Johnson & Johnson asked U.S. regulators Thursday to clear the world’s first single-dose COVID-19 vaccine, an easier-to-use option that could boost scarce supplies.
J&J’s vaccine was safe and offered strong protection against moderate to severe COVID-19, according to preliminary results from a massive international study.
AdDr. Peter Marks, FDA’s vaccine chief, has cautioned against making comparisons before the evidence is all in.
OTHER OPTIONSIn large U.S. studies, two doses of the Pfizer and Moderna vaccines proved 95% protective against any symptomatic COVID-19.
J&J also is studying a two-dose version of its vaccine, but results won’t be available for several more months.